EQRx Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 300

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.07B

  • Investors
  • 3

EQRx General Information

Description

EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.

Contact Information

Website
www.eqrx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 50 Hampshire Street
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 50 Hampshire Street
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EQRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 09-Nov-2023 $1.07B Completed Generating Revenue
4. PIPE 17-Dec-2021 Completed Generating Revenue
3. Reverse Merger 17-Dec-2021 Completed Generating Revenue
2. Early Stage VC (Series B) 11-Jan-2021 $570M $770M Completed Startup
1. Early Stage VC (Series A) 12-Jan-2020 $200M $200M Completed Startup
To view EQRx’s complete valuation and funding history, request access »

EQRx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view EQRx’s complete cap table history, request access »

EQRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclini
Drug Discovery
Cambridge, MA
300 As of 2023

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EQRx Competitors (1)

One of EQRx’s competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altimmune Formerly VC-backed Gaithersburg, MD
You’re viewing 1 of 1 competitors. Get the full list »

EQRx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EQRx Former Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Andreessen Horowitz Venture Capital Minority
Arboretum Ventures Venture Capital Minority
Avidity Partners Asset Manager Minority
You’re viewing 5 of 24 investors. Get the full list »

EQRx Investments & Acquisitions (4)

EQRx’s most recent deal was a Merger/Acquisition with CM Life Sciences III. The deal was made on 17-Dec-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CM Life Sciences III 17-Dec-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Siduma Therapeutics 16-Nov-2021 Early Stage VC Drug Discovery
Hansoh Pharmaceutical (Aumolertinib License) 22-Jul-2020 Corporate Asset Purchase Buildings and Property
Crimson BioPharm 04-Oct-2019 Seed Round Pharmaceuticals
To view EQRx’s complete investments and acquisitions history, request access »

EQRx ESG

Risk Overview

Risk Rating

Updated June, 30, 2023

27.56 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view EQRx’s complete esg history, request access »

EQRx FAQs

  • When was EQRx founded?

    EQRx was founded in 2019.

  • Where is EQRx headquartered?

    EQRx is headquartered in Cambridge, MA.

  • What is the size of EQRx?

    EQRx has 300 total employees.

  • What industry is EQRx in?

    EQRx’s primary industry is Drug Discovery.

  • Is EQRx a private or public company?

    EQRx is a Private company.

  • What is the current valuation of EQRx?

    The current valuation of EQRx is .

  • What is EQRx’s current revenue?

    The current revenue for EQRx is .

  • How much funding has EQRx raised over time?

    EQRx has raised $1.97B.

  • Who are EQRx’s investors?

    ARCH Venture Partners, Alexandria Venture Investments, Andreessen Horowitz, Arboretum Ventures, and Avidity Partners are 5 of 24 investors who have invested in EQRx.

  • Who are EQRx’s competitors?

    Altimmune is a competitor of EQRx.

  • When was EQRx acquired?

    EQRx was acquired on 09-Nov-2023.

  • Who acquired EQRx?

    EQRx was acquired by Revolution Medicines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process